New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

New Delhi: Sun Pharma Labs has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Their baseline estimated glomerular filtration rate (eGFR) was less than 45 mL/min/1.73 m 2 ... Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

At the Annual General Meeting on 27 March 2025, the Board of Directors will propose a final dividend of DKK 7.90 for 2024 per share. The expected total dividend for 2024 will increase 21% to DKK 11.40 ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

1 Eli Lilly and Company (NYSE ... in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's ...